Home Blog Page 812

Hyundai Motor Company Launches IONIQ Lineup Brand in China with the Premiere of Two New Concept Cars

  • Hyundai Motor officially launches its all‑electric IONIQ lineup brand in China, signaling a renewed commitment to the NEV market
  • Two new design concepts preview the future direction of the IONIQ lineup brand ahead of Auto China 2026
  • The VENUS Concept sedan and EARTH Concept family SUV debut as two ‘planets’ in a new ‘universe’ of models

BEIJING and SEOUL, South Korea, April 10, 2026 /PRNewswire/ — Hyundai Motor Company officially launched its all-electric IONIQ lineup brand in China, unveiling two design concept cars at the IONIQ brand launch event in Beijing ahead of Auto China 2026 (‘Beijing Auto Show’) on April 24.

Hyundai Motor Teases Official Launch of IONIQ Brand in China
Hyundai Motor Teases Official Launch of IONIQ Brand in China

Alongside the concepts, Hyundai Motor presented a strategy aimed at strengthening its position in the Chinese market, expanding the IONIQ brand’s lineup beyond products into a mobility experience.

The two all-electric concept cars developed for China — the VENUS Concept, a trend-setting sedan, and the EARTH Concept, a dependable family SUV — signal the beginning of this new chapter. Both concepts highlight Hyundai Motor’s readiness for China’s new energy vehicle (NEV) market.

“Starting with the two concept cars unveiled today, we will continue to present products that reflect deep insight into Chinese customers and our genuine commitment to this market. Built on IONIQ’s uncompromising principles of world-class safety and quality, we will soon introduce production models that seamlessly combine the smart driving and smart cabin experiences that Chinese consumers demand.” – Li Fenggang, President at Beijing Hyundai Motor Company

What Is IONIQ and How Will the lineup Brand Be Tailored for China?

As Hyundai Motor’s dedicated all-electric vehicle lineup brand, IONIQ has quickly become a global benchmark for innovation, design and quality. Built on critically acclaimed models such as the IONIQ 5, IONIQ 6 and IONIQ 9, the EV lineup reflects Hyundai Motor’s advanced electrification capabilities and human-centric mobility vision.

IONIQ’s global excellence is further underscored by multiple industry recognitions, including ‘hat-trick’ victories for the IONIQ 5 and IONIQ 6 at the World Car Awards. High-performance models such as the IONIQ 5 N and IONIQ 6 N have also reinforced the brand’s leadership in electric performance, with IONIQ 6 N most recently named 2026 World Performance Car.

In China, IONIQ will evolve beyond a product lineup into a broader mobility ecosystem tailored to local customers. While maintaining Hyundai Motor’s globally proven standards in safety and quality, IONIQ is being redefined through localized technologies, services and user experiences for China’s fast-evolving NEV market.

As part of this strategy, Hyundai Motor is introducing a unique naming convention tailored for China. Future IONIQ models will be named after ‘planets’, symbolizing how each vehicle orbits around the customer — the central focus of this new IONIQ universe.

What Are the Two IONIQ Concept Cars for the Chinese Market?

The VENUS and EARTH concepts are the first tangible results of Hyundai Motor’s new China strategy, serving as a design ‘barometer’ for future IONIQ production models. Guided by the ethos ‘Lead, don’t follow‘, the two concepts feature unique single-curve silhouettes that are instantly recognizable and emotionally distinctive, delivering a lasting and impactful first impression.

VENUS (Iconic Sedan): Inspired by the brightest planet’s timeless beauty, VENUS presents a new icon for sedans.

  • Exterior: Finished in striking ‘Radiant Gold’ that captures a narrative of breakthrough, exploration and glory, its high-tech exterior features a lightweight, frame-structured roof and a transparent spoiler. A unique one-curve silhouette further defines its distinctive profile, creating a sleek, characterful design identity.
  • Interior: The driver-focused, wrap-around cockpit evokes Venus’s glowing atmosphere with layered mood lighting. A strong material contrast between soft suede and solid, chrome-gold seatback covers enhances the premium feel, while a friendly ‘Lumi’ character is integrated into the design for a playful connection between driver and vehicle.

EARTH (Powerful SUV): Embodying the vitality and biological balance of our home planet, EARTH is a bold and powerful family SUV.

  • Exterior: Finished in ‘Aurora Shield’, the balance between sharp edges and sculpted volumes creates a futuristic image, alongside robust details such as EARTH’s skid plates and exposed bolt accents.
  • Interior: The interior is a comfortable ‘small Earth’, featuring innovative ‘air-hug’ seats made of soft air modules. Serene mood lighting that mimics tree shadows and clever ‘shy-tech’ elements create a calm and breathable space, while a fun ‘Aero’ character and hidden map patterns of Beijing offer a sense of discovery.

“We chose to be ‘The Origin’. Something entirely new — recognizable at a glance from a distance, with a powerful presence on the road, and delivering what we call a ‘Best in First Impression’. ‘The Origin’ is our declaration: ‘Lead, don’t follow’. It is the point from which our movement begins. Our ambition is to set a new direction.” – Simon Loasby, Senior Vice President and Head of Hyundai Design Center at Hyundai Motor Company

How Is Hyundai Motor Redefining Its Approach to the Chinese Market?

At the event, Hyundai Motor also provided a glimpse into exclusive IONIQ technologies tailored for Chinese customers. Key advancements include the introduction of autonomous driving systems developed with local partners and the adoption of market-specific solutions, such as extended range electric vehicles (EREVs). These technologies reflect Hyundai Motor’s commitment to returning to the market with a truly human-centric philosophy, prioritizing tangible benefits that address the real-world needs of Chinese consumers.

To support this vision, Hyundai Motor has also released an IONIQ brand launch film under the message “Open Your Universe,” further illustrating the brand’s direction.

Further details will be unveiled during Hyundai Motor’s press conference at Auto China 2026 on April 24, at Hall E4 of the China International Exhibition Center (Shunyi Hall) in Beijing.

More information about Hyundai Motor and its products can be found at https://www.hyundai.com/worldwide/en/

 

No More Seasonal Blues! iHerb Launches Spring “Defense-Focused” Health Guide: Discovering 6 Nutritional Essentials

HONG KONG, April 10, 2026 /PRNewswire/ — As spring arrives, drastic changes in temperature and environmental humidity often lead to “seasonal discomforts” such as fatigue and disrupted routines. Recognizing the rising demand for spring skincare and nutritional supplements, global cross-border health e-commerce platform iHerb has launched the “Spring Defense Supplement Guide.” It features 6 cost-effective health products, ranging from daily nutritional supplements to lifestyle care, to support consumers through the seasonal transition.

iHerb has selected 6 spring supplement essentials to accompany consumers in welcoming the changing season.
iHerb has selected 6 spring supplement essentials to accompany consumers in welcoming the changing season.

As a world-renowned online retailer of health and wellness products, iHerb offers over 50,000 products, covering vitamins, sports nutrition, beauty and personal care, natural foods, and home lifestyle items. Shipped through fulfillment centers in the U.S. and Asia, the platform serves over 180 countries and regions worldwide, allowing consumers to easily purchase popular international health products. To address the unpredictable spring weather and pace of life, iHerb has organized three daily supplement categories—nutritional support, sleep relaxation, and daily functional nutrition—to help consumers maintain a good state amidst their busy lives.

Maintaining Inner and Outer Balance: Daily Nutritional Supplements for Seasonal Changes

During seasonal transitions, issues like skin instability and disrupted life rhythms are common; thus, starting adjustments with daily nutritional supplements is particularly important. The popular supplement “Thorne Zinc Picolinate,” known for its zinc nutritional support, has become a top choice for many consumers during this period. For home life, the highly popular “Mrs. Meyer’s Clean Day Hand Soap,” featuring a birchwood scent and plant-based formula, provides a refreshing forest woody aroma that brings a sense of relaxation to daily hand cleaning.

Quality Sleep and Relaxation: Recharging for the Rhythm of Life

Good sleep quality is an essential foundation for maintaining the rhythm of life. “Swanson Albion Magnesium Glycinate” provides mineral support and serves as a daily source of magnesium nutrition, attracting attention from those who value a balanced lifestyle. For those working long hours or needing to maintain focus, the “Brain Health Veggie Capsules” from iHerb’s popular brand California Gold Nutrition offer multifaceted nutritional support, serving as a pillar for busy professionals.

Functional Nutritional Supplements: Welcoming Spring Vitality

As the weather gradually warms up, the demand for outdoor activities and exercise increases. “Nutricost HMB Capsules” provide the daily nutritional support needed for the active population, whether for home yoga or outdoor jogging. Furthermore, with the rising popularity of concerts and sports events, daily eye care supplements are also gaining attention. iHerb recommends “Doctor’s Best Natural Vision Enhancers,” which contain not only lutein and zeaxanthin but also Omega-3, DHA, and EPA to provide the comfort and nourishment required by modern individuals for long durations.

Limited-Time Promo Code Code: 22% Off at Checkout

In addition to product recommendations, iHerb is simultaneously launching several limited-time promotions. iHerb stated that through its diverse range of health products and cross-border direct shipping services, it hopes consumers can easily replenish necessary nutrients during the seasonal change. To thank consumers for their long-term support, iHerb is offering a special value deal for Hong Kong consumers in the spring of 2026.  From April 10 to April 24, use the promo code “78IHERB” at the iHerb official website checkout to enjoy 22% off. Grab the opportunity for spring replenishment and boost healthy energy into your daily life.

iHerb:Your One-Stop Global Health Destination

Headquartered in California, USA, iHerb is a leading global online retail brand for health and wellness products. iHerb’s greatest advantage is providing Hong Kong consumers with a secure channel that eliminates the need for purchasing agents and the fear of counterfeit goods. All products are shipped directly from fulfillment centers in the U.S. and Asia, guaranteeing authentic products and an extremely convenient shopping experience:

  • Fast Delivery: Arriving as early as the next day after ordering.
  • Free Shipping: Enjoy free shipping on orders over HKD$300.

From vitamins and nutritional supplements to health essentials for the family, now is the best time to shop. If you want to shop smart and with peace of mind, visit the iHerb official website now and don’t let thesehigh-value deal slip away!

About iHerb (Official Website: https://hk.iherb.com/)

iHerb is a world-renowned cross-border e-commerce platform from the United States, focusing on providing high-quality health foods, nutritional supplements, beauty and personal care, and lifestyle products. With over 50,000 selected products across the site, serving more than 180 countries and regions, iHerb is committed to allowing global consumers to obtain healthy and beautiful choices at reasonable prices. All products are shipped directly from multiple advanced fulfillment centers in the U.S. and Asia, maintaining product freshness under full cold chain and temperature-controlled warehouse management. iHerb also continues to strengthen its multilingual customer service and local payment methods to ensure a safe, transparent, and convenient shopping experience for users worldwide.

 

Countries pledge $3.9 billion to Global Environment Facility towards ambitious ninth replenishment

Four-year financing commitment supports accelerated action by developing countries towards 2030 environmental goals

WASHINGTON, April 10, 2026 /PRNewswire/ — Donor countries have pledged an initial $3.9 billion to the Global Environment Facility (GEF) for its ninth replenishment cycle, in a powerful demonstration of commitment to meeting international environmental goals through multilateral cooperation.

The significant funding will enable the GEF to bolster investment in nature-positive development, helping developing countries address their most urgent priorities and generate global environmental benefits that help people as well as ecosystems.

Further pledges in support of a robust and ambitious four-year financing round are expected by the GEF Council meeting at the end of May, when the final replenishment package will be approved.

Read the full press release in English, French, or Spanish

“This replenishment sends a clear message: the world is not giving up on nature even in a time of competing priorities. Our donor countries have risen to the challenge and made bold commitments towards a more positive future for the planet. The coming four years of the GEF-9 cycle will reflect this high-ambition push to achieve the 2030 environmental goals,” said Claude Gascon, Interim CEO and Chairperson of the GEF.

The GEF-9 investment cycle will cover the period from July 2026 to June 2030. Four overarching priorities will define the ambition and approach for the GEF over the next four years:

  • Integration and Integrated Programs
  • Blended Finance
  • Whole-of-Government and Whole-of-Society Approaches
  • Robust Funding for LDCs and SIDS, and a Significant Increase in Support to IPLCs

The 71st GEF Council meeting will be held in Samarkand, Uzbekistan from May 31 to June 3, 2026. The meeting will take place in advance of the Eighth GEF Assembly, when individual country pledges will be publicly announced.

About the GEF

The Global Environment Facility (GEF) is the world’s largest multilateral fund for the environment. Its family of funds works together to address the planet’s most pressing challenges in an integrated way. Its financing helps developing countries address complex challenges and work towards meeting international environmental goals. Over the past three decades, the GEF has provided more than $27 billion in financing, primarily as grants, and mobilized another $155 billion for country-driven priority projects. For more information, visit: www.thegef.org

Phuc Yen Industrial Park a catalyst for investment in Phu Tho


PHU THO, VIETNAM – Media OutReach Newswire – 10 April 2026 – Approved by the Phu Tho People’s Committee, a joint venture between Vinh Phuc International Services and Industrial Zone Joint Stock Company (VISIZ) and SHINEC joint Stock Company officially broke ground on the Phuc Yen Industrial Park (Phuc Yen IP) infrastructure project on April 9.

A view of the Phuc Yen Industrial Park in Phuc Yen Ward in Phu Tho Province. — Photo courtesy of the firm
A view of the Phuc Yen Industrial Park in Phuc Yen Ward in Phu Tho Province. — Photo courtesy of the firm

Phuc Yen IP covers 111.3 hectares in Phuc Yen Ward in the northern province of Phú Thọ, with a total investment of approximately VNĐ1.98 trillion and a 50-year operating licence.

Regarded as a key project in the province’s economic development strategy, Phuc Yen IP is expected to become a magnet for high-quality investment, particularly from enterprises in technology and electronics, precision engineering, supporting industries and logistics.

Strategic location and world-class infrastructure

Phuc Yen IP enjoys outstanding connectivity, with direct access to the Noi Bai – Lao Cai Expressway, a location approximately 10 minutes from Noi Bai International Airport and strong links to major economic hubs in Hà Nội, Phú Thọ and neighbouring provinces.

All technical infrastructure is built to international standards, including internal roads, high-capacity power supply, water supply and drainage systems, a centralised wastewater treatment plant and urban landscaping – enabling businesses to begin operations immediately upon land handover.

Development timeline

  • Phase 1 (Q1/2024 – Q1/2026): Legal procedures, site clearance, construction commencement
  • Phase 2 (Q2/2026 – Q1/2027): Full infrastructure construction – site levelling, internal roads, power and water system, wastewater treatment – culminating in project completion and handover

VISIZ General Director Nguyen Hai Tung said on behalf of the investor consortium: “We are fully committed to mobilising all available resources to deliver this project on schedule, ensuring synchronised, high-quality and modern construction standards.

“Phuc Yen IP is more than a production facility – it is a sustainable industrial ecosystem where investors can build and grow their operations with confidence over the long term.”

Socio-economic impact

At full capacity, Phuc Yen IP is expected to attract dozens of domestic and international investors, generate thousands of stable employment opportunities, and contribute meaningfully to annual State budget revenues. The park will serve as a catalyst for commercial services, urban development and industrial real estate growth across Phuc Yen Ward and surrounding areas.

Media Contact:

Hotline: (+84) 333 699 996

Email: phucyen@visiz.com.vn

Website: www.visiz.com.vn

Hashtag: #VISIZ #SHINEC

The issuer is solely responsible for the content of this announcement.

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis (AD), has been formally accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This acceptance marks a critical milestone in the company’s clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals’ transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.

Atopic dermatitis is a chronic, relapsing, inflammatory skin disease characterized by pruritus and impaired skin barrier function, significantly impacting patients’ quality of life. Despite the availability of various treatment options, a substantial proportion of patients have inadequate responses or face long-term safety challenges, leaving significant unmet medical needs.

The NDA submission is primarily supported by positive results from a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial (NCT06277245) conducted in China. The study demonstrated that both dose groups of zemprocitinib achieved highly statistically significant improvements (p < 0.0001) compared with placebo across primary and key secondary endpoints, while also exhibiting a favorable safety and tolerability profile.

Dr. Zhao-Kui (ZK) Wan, Founder and Chief Executive Officer of Lynk Pharmaceuticals said: “The submission and acceptance of the NDA for zemprocitinib represent a significant achievement in our continued focus on autoimmune and inflammatory diseases. We remain committed to developing innovative medicines with strong clinical value and global competitiveness, and we look forward to bringing this therapy to patients with atopic dermatitis as soon as possible.”

About Zemprocitinib
Zemprocitinib is a second-generation selective JAK1 inhibitor with best-in-class potential. In addition to the completed 52-week Phase III clinical trial in atopic dermatitis, the Phase III clinical trial in rheumatoid arthritis (RA) has progressed into the treatment extension phase. A Phase III trial in ankylosing spondylitis (AS) is currently ongoing, and a Phase II trial in vitiligo is in the startup phase.

Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic potential across a range of indications, including AD, RA, and AS. Compared with first-generation JAK inhibitors that have lower selectivity, zemprocitinib exhibits greater selectivity for JAK1, which may reduce the risk of off-target adverse effects. Across all completed or unblinded clinical studies, including Phase II trials in AD, RA, and AS; the Week 24 data readout from the Phase III RA study; and the completed Phase III trial in AD, zemprocitinib has demonstrated a favorable safety and tolerability profile. The incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) was comparable to placebo, and laboratory safety parameters were generally well maintained. Overall, its safety profile is consistent in all completed or unblinded studies and compares favorably with those of reported JAK inhibitors.

About Lynk Pharmaceuticals
Lynk Pharmaceuticals is a clinical-stage biotechnology company founded by senior drug R&D leaders and executives from Pfizer, Merck, and Johnson & Johnson. The company is dedicated to the discovery and development of innovative therapies for immune and inflammatory diseases. Driven by a commitment to address significant unmet medical needs, Lynk Pharmaceuticals aims to deliver differentiated therapies with global impact. To date, the company has independently or jointly advanced multiple innovative drug candidates and successfully completed numerous clinical studies.

 

Hankook Strengthens Motorsport Presence at the 2026 Hi-Tec Oils Bathurst 6 Hour

  • Hankook proves its top-tier technological leadership by serving as the official tyre supplier to the ‘Bathurst 6 Hour’ for the second consecutive year
  • Ventus TD delivered consistent grip, stability and durability across six hours of racing
  • Motorsport-derived R&D reinforces Hankook’s global premium brand positioning

SYDNEY, April 10, 2026 /PRNewswire/ — Global leading tyre company Hankook Tire & Technology (Hankook) announced that Hankook Tyre Australia successfully served as the official tyre supplier to the 2026 Bathurst 6 Hour for the second consecutive year, held from April 3 to 5 at Mount Panorama Circuit. Through this six-hour endurance competition, Hankook reinforced its commitment to high-performance motorsport and advanced tyre technology.

[Photo] 2026 Bathurst 6 Hour
[Photo] 2026 Bathurst 6 Hour

Marking the 10th edition of the Bathurst 6 Hour, the event featured 69 cars competing across multiple classes. Held on the demanding 6.2-kilometre Mount Panorama Circuit, the race stands as Australia’s premier production car endurance event, known for its combination of high-speed straights, technical corners and significant elevation changes.

The 2026 race featured intense competition, with multiple lead changes and strategic battles throughout the six-hour duration. Supercars driver Thomas Randle, alongside Ben and Michael Kavich, secured overall victory in a closely contested finish, highlighting the importance of consistency, strategy and performance in endurance racing at Mount Panorama.

As the official tyre supplier, Hankook Tyre Australia supported the event with its advanced motorsport tyre technology. Since 2025, all competing vehicles have been equipped with the high-performance semi-slick racing tyre ‘Ventus TD’, ensuring stable race performance. Engineered to perform under demanding conditions, Ventus TD delivers high levels of dry grip, consistent handling performance and enhanced durability throughout extended race sessions.

In an endurance racing environment such as Bathurst, sustained tyre performance is critical. Ventus TD demonstrated stable grip and predictable handling across extended stints, enabling teams to optimise race strategy. Its construction and compound are designed to enhance durability, heat resistance and reduced wear under varying track conditions. The tyre’s optimised contact patch and tread design enable balanced load distribution, contributing to consistent performance.

In Australia, Hankook continues to strengthen its sales competitiveness with its flagship tyre brand ‘Ventus’ while actively supporting major local motorsport events, including the First Focus Radical Cup Australia Series, the Precision National Sports Sedans Series and the Hyper Racer Hankook Australian Drivers Championship, thereby expanding its global motorsport footprint.

Hankook Tyre Australia’s participation in the Bathurst 6 Hour reflects its broader commitment to supporting motorsport platforms that demand high levels of performance, safety and technological innovation. Leveraging its global expertise in tyre development, Hankook continues to demonstrate its top-tier technological leadership. Hankook continues to supply racing tyres and sponsor teams across more than 70 major global motorsport competitions, including the ABB FIA Formula E World Championship and the FIA World Rally Championship (WRC), further solidifying the global premium positioning of its brand.

Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI, April 10, 2026 /PRNewswire/ — Oricell Therapeutics Holdings Limited (“Oricell”), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.

Proceeds will be strategically allocated to accelerate Oricell’s global expansion and clinical development, while strengthening its technological capabilities and paving the way to capital market milestones.

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo (Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.

OriCell’s lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.

Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.

Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: “This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena.”

Mr. Shan Fu, Managing Partner at Vivo Capital, commented: “While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry’s toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated ‘Platform and Pipeline’ strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell’s expansion into international markets.”

Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: “As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide.”

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Powered by a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies. This technical prowess and global strategy are exemplified by the development of another core candidate, OriCAR-017. Supported by compelling data from IIT in China, the program paved the way into global development, rapidly securing IND approvals from both China NMPA and US FDA, along with FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD). OriCAR-017 has demonstrated a favorable safety profile and robust efficacy in both IIT and registrational clinical trials, with data featured at leading global conferences including 2022 ASCO, 2022 EHA, 2024 ASCO, and published in top-tier academic journals The Lancet Haematology. These milestones underscore Oricell’ capabilities in regulatory strategy, clinical development, and global execution, reflecting its commitment to transforming the future of cell therapy and delivering new hope to patients worldwide. For more information, please visit: www.oricell.com.

Forward-Looking Statements

This press release contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited (“the Company” or “Oricell”). The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sandmark Crypto Intelligence Report Shows Credible Insight Drives Investment Confidence

  • 38% of finance professionals who personally hold crypto view it as a growth opportunity with strong upside potential
  • 96% of professional investors are optimistic about crypto’s future as an asset, vs just 39% of beginner investors
  • 25% of finance professionals describe crypto primarily as a high-risk asset — falling to just 1 in 10 among those who personally invest
  • 8% of respondents cite payments utility as a reason to hold crypto, yet wider merchant acceptance and regulatory integration are seen as critical drivers of future adoption
  • 42% of finance professionals cite regulatory uncertainty as their primary barrier to greater institutional involvement

GENEVA, April 10, 2026 /PRNewswire/ — Sandmark has today published the first edition of its Crypto Intelligence Report, uncovering how credible and reliable intelligence are building real conviction among finance professionals and investors.

Michelle Fotopoulou, Chief Marketing Officer at Sandmark, commenting on the Crypto Intelligence Report
Michelle Fotopoulou, Chief Marketing Officer at Sandmark, commenting on the Crypto Intelligence Report

The study captured the attitudes and behaviours of over 5,000 finance professionals and crypto investors across Australia, Brazil, India, Singapore, South Korea, UAE, UK and the US. Conducted in partnership with the global consumer audience insights platform GWI, the report fills a significant gap in existing market research by focusing specifically on the financially literate crypto investors: those working within and alongside the financial industry.

“Most crypto research focuses on retail sentiment. We wanted to understand how finance professionals – people who work with risk and capital every day – actually perceive and engage with crypto. What we found challenges a number of assumptions,” said Michelle Fotopoulou, Chief Marketing Officer at Sandmark.

Experience contextualizes risk

Just one in ten finance professionals who own crypto perceive it as high risk, compared to 25% of the wider professional finance community. Optimism and confidence rise in line with active participation, peaking among institutional investors and long-term holders. Beginners remain the least certain. The data consistently shows that hands-on experience, supported by reliable market intelligence, is what builds genuine conviction.

Regulation is recruitment

Regulatory uncertainty remains the primary barrier to broader institutional participation, alongside volatility and governance concerns. Yet across all respondent groups, crypto is viewed as a long-term strategic asset with strong upside potential, rather than a short-term trade. As regulatory clarity improves, the market’s next growth phase is widely expected to be led by institutions.

Michelle said: “Strong regulation acts as a catalyst for engagement. As jurisdictions put protections in place, activity accelerates, with greater confidence unlocking broader adoption.”

Public figures: formative but divisive

High-profile individuals continue to play an outsized role in shaping sentiment, often in conflicting ways. Among a pre-defined shortlist of public figures, Elon Musk drives the strongest positive sentiment (51%), while Donald Trump generates the most negative (38%), despite also ranking as the second most cited positive influence (17%). Among crypto holders who identify Musk as their strongest positive influence, 77% report high optimism toward crypto’s future as an asset. The study reflects how public figures are capable of simultaneously amplifying enthusiasm and undermining trust.

An evolving but maturing market

Michelle concluded, “It’s fascinating to see the evolution of sentiment in the crypto market, particularly in the case of institutions and finance professionals. While social media drives discovery, real market data is in higher demand. Investors need consistent, actionable market intelligence to understand the evolving crypto ecosystem.”

The Sandmark Crypto Intelligence Report is available here.

About Sandmark

Established in 2025 by a Switzerland-based entrepreneur, Sandmark operates internationally with editorial hubs in Europe, the Middle East, Asia and North America. Sandmark is led worldwide by traditional and new financial media professionals who have decades of experience covering a range of markets from banking to commodities, and FX trading to equities research.

The Sandmark Team is comprised of 20+ global employees – including journalists, researchers and data analysts – that are united in the mission to deliver clear, credible, and context-rich reporting. 

Sandmark Crypto Intelligence Report: first edition of key trends shaping the digital asset landscape
Sandmark Crypto Intelligence Report: first edition of key trends shaping the digital asset landscape